In small test, experimental prostate drug shows promise
An experimental drug is showing what some experts say is intriguing effectiveness in treating a major cause of death and disability for men with prostate cancer — tumors that have spread to the bone.
The results of early testing of the drug, to be presented at a cancer conference in Berlin on Thursday, would be another piece of good news this week for men with the disease. On Wednesday, a federal advisory committee said there was adequate evidence that the already marketed prostate cancer drug Provenge, developed by Dendreon, prolongs lives.
- Providers' Push to Consolidate Roils Payers
- Former NQF Co-Chair Linked to Conflicts of Interest in Journal Probe
- As Retail Clinics Surge, Quality Metrics MIA
- RN Named Chief Patient Experience Officer
- Medicare Cost, Quality Data Tools Weak, Says GAO
- No Employee Satisfaction, No Patient-Centered Culture
- Six Not-So-Good Reasons for Avoiding Population Health
- In PCMH, the 'P' is Not for 'Physician'
- Population Health Pays Off for NY Collaborative
- How Simple Data Analytics is Driving Physician Incentives